Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

104

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

104 results for “Ifosfamide”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov32/100

Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment

ClinicalTrials.gov study NCT02812654. IPD Sharing: UNDECIDED. Countries: 1. Publications: 10.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients

ClinicalTrials.gov study NCT01749072. IPD Sharing: Not stated. Countries: 1. Publications: 5.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

ClinicalTrials.gov study NCT00061984. IPD Sharing: Not stated. Countries: 11. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma

ClinicalTrials.gov study NCT04690231. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Ifosfamide With or Without Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cancer of the Uterus

ClinicalTrials.gov study NCT00003128. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma

ClinicalTrials.gov study NCT03514381. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide

ClinicalTrials.gov study NCT00358540. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma

ClinicalTrials.gov study NCT00001300. IPD Sharing: Not stated. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients

ClinicalTrials.gov study NCT03815474. IPD Sharing: NO. Countries: 1. Publications: 2.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung Cancer

ClinicalTrials.gov study NCT01752517. IPD Sharing: Not stated. Countries: 1. Publications: 9.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma

ClinicalTrials.gov study NCT03342300. IPD Sharing: YES. Countries: 1. Publications: 17.

controlledIPD-YESFeb 2026View details →
zenodo28/100

Figure 6 from: AlMotwaa SM (2021) Coupling Ifosfamide to nanoemulsion-based clove oil enhances its toxicity on malignant breast cancer and cervical cancer cells. Pharmacia 68(4): 779-787. https://doi.org/10.3897/pharmacia.68.e68291

Figure 6 Relative fluorescence intensity of nuclei at various concentrations of the studied formulas analyzed using Image J 1.43. Data are expressed as mean ± SE (n=3). Asterisks denote statistical significance (***p < 0.001 considered as very highly significant, **0.001 ≤ p < 0.01 considered as highly significant, and *0.01 ≤p < 0.05 considered as significant).

opencc-by-4.0Oct 2021View details →
zenodo28/100

Figure 5 from: AlMotwaa SM (2021) Coupling Ifosfamide to nanoemulsion-based clove oil enhances its toxicity on malignant breast cancer and cervical cancer cells. Pharmacia 68(4): 779-787. https://doi.org/10.3897/pharmacia.68.e68291

Figure 5 Fluorescence microscopic images of changes in nuclear morphology of MCF-7 cells treated with various concentrations of the tested formulas for 24h, as revealed using DAPI stain (n = 3).

opencc-by-4.0Oct 2021View details →
zenodo28/100

Figure 4 from: AlMotwaa SM (2021) Coupling Ifosfamide to nanoemulsion-based clove oil enhances its toxicity on malignant breast cancer and cervical cancer cells. Pharmacia 68(4): 779-787. https://doi.org/10.3897/pharmacia.68.e68291

Figure 4 Fluorescence microscopic images of changes in nuclear morphology of HeLa cells treated with various concentrations of the tested formulas for 24h, as revealed using DAPI stain (n = 3).

opencc-by-4.0Oct 2021View details →
zenodo28/100

Figure 2 from: AlMotwaa SM (2021) Coupling Ifosfamide to nanoemulsion-based clove oil enhances its toxicity on malignant breast cancer and cervical cancer cells. Pharmacia 68(4): 779-787. https://doi.org/10.3897/pharmacia.68.e68291

Figure 2 Cell viability of HeLa and MCF-7 cells after 24h of incubation with clove oil-based NE at various concentrations. Data are expressed as mean ± SE (n = 3). Asterisks denote statistical significance (***p < 0.001 considered as very highly significant, **0.001 ≤ p < 0.01 considered as highly significant, and *0.01 ≤ p < 0.05 considered as significant).

opencc-by-4.0Oct 2021View details →
zenodo28/100

Figure 3 from: AlMotwaa SM (2021) Coupling Ifosfamide to nanoemulsion-based clove oil enhances its toxicity on malignant breast cancer and cervical cancer cells. Pharmacia 68(4): 779-787. https://doi.org/10.3897/pharmacia.68.e68291

Figure 3 Photomicrographs of cellular morphologies at IC50 after 24 h incubation (n=3). The arrows colored brown, green, red, black, and dark red indicate membrane blebbing, cytoplasmic vesicles, enlarged nuclei, loss of membrane integrity, and extracellular vesicles, respectively.

opencc-by-4.0Oct 2021View details →
zenodo28/100

Figure 1 from: AlMotwaa SM (2021) Coupling Ifosfamide to nanoemulsion-based clove oil enhances its toxicity on malignant breast cancer and cervical cancer cells. Pharmacia 68(4): 779-787. https://doi.org/10.3897/pharmacia.68.e68291

Figure 1 Preparation and characterization of clove oil-based NE. A preparation of formulated NEsB, C Z-average diameter (n=3); D, E Zeta potential for n=3 using Zetasizer Malvern, UK). Asterisks denote statistical significance (**0.001 ≤ p < 0.01 considered as highly significant, and *0.01 ≤ p < 0.05 considered as significant).

opencc-by-4.0Oct 2021View details →
ClinicalTrials.gov28/100

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

ClinicalTrials.gov study NCT03283696. IPD Sharing: NO. Countries: 3. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery

ClinicalTrials.gov study NCT00880542. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin

ClinicalTrials.gov study NCT00423852. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record